JANUET 50/500 MG TABLETS

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

METFORMIN HYDROCHLORIDE 500 MG; SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 50 MG

Commercializzato da:

MERCK SHARP & DOHME ISRAEL LTD

Codice ATC:

A10BA02

Forma farmaceutica:

TABLETS

Via di somministrazione:

PER OS

Prodotto da:

MERCK SHARP & DOHME CORP., USA

Gruppo terapeutico:

METFORMIN

Indicazioni terapeutiche:

Januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use:Januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.Januet has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januet.

Data dell'autorizzazione:

2009-03-01